Download PDF
CC BY-NC-ND 4.0 · J Lab Physicians 2020; 12(01): 44-48
DOI: 10.1055/s-0040-1714195
Original Article

Prostate-Specific Antigen Density: A Measurement to Differentiate Benign Hypertrophy of Prostate from Prostate Carcinoma

Chandan Kumar Nath
1   Department of Biochemistry, NEIGRIHMS, Shillong, Meghalaya
,
Bhupen Barman
2   Department of General Medicine, NEIGRIHMS, Shillong, Meghalaya
,
Pranjal Phukan
3   Department of Radio-diagnosis and Imaging, NEIGRIHMS, Shillong, Meghalaya
,
Stephen L. Sailo
4   Department of Urology, NEIGRIHMS, Shillong, Meghalaya
,
Biswajit Dey
5   Department of Pathology, NEIGRIHMS, Shillong, Meghalaya
,
Indrajit Nath
6   Department of Biochemistry, North Bengal Medical College, Sushrutanagar, Darjeeling District, West Bengal, India
,
Purnima Rajkhowa
7   Department of Microbiology, Silchar Medical College, Silchar, Assam
› Author Affiliations Funding This study was funded by an intramural research grant received from the North Eastern Indira Gandhi Regional Institute of Health and Medical sciences (NEIGRIHMS), Shillong (NEIGR-Esst-I/7/2016).
› Further Information
Also available at
   Permissions and Reprints

Abstract

Background Determination of isolated prostate-specific antigen (PSA) in asymptomatic individuals has not demonstrated sufficient sensitivity and specificity to be useful in the routine evaluation of prostate disease. To enhance the accuracy of serum PSA we have used a proportion of serum PSA and prostate volume, which we refer to as prostate-specific antigen density (PSAD). Prostate volume in this study was calculated using transrectal ultrasonography (TRUS).

Materials and Methods A total of 106 patients with prostatic disease clinically confined to the prostate glands were evaluated.

Results and Observation The mean PSAD for prostate cancer was 0.15 ± 0.01 while that for benign hypertrophy of the prostate (BPH) was 0.11 ± 0.02 (p < 0.05). Significant difference (p < 0.05) was noted in the prostate volume in these two groups with the mean prostate volume measured by TRUS in the BPH to be 53.85 ± 9.71 mL compared with 58.14 ± 7.48 mL in the carcinoma. PSA density of 0.13 ng/mL can be used as a cutoff for the individual in our set-up who should go for prostate biopsy with sensitivity and specificity of over 90%.

Conclusion These results suggest that PSAD may be useful in distinguishing BPH and prostate cancer.

Keywords

prostate-specific antigen density - carcinoma - transrectal ultrasonography - benign hypertrophy


Publication History

Article published online:
24 July 2020

© .

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Scher HI, Eastham JA. Benign and malignant diseases of the prostate. In: Kasper DL, Fauci AS, Hauser SL, Longo DL, Larry JJ, Loscaizo J. eds. Harrison's Principles of Internal Medicine. 20th ed. New York, NY: McGraw-Hill Education; 2018: 796-805
    Search in Google Scholar
  • 2 Hariharan K, Padmanabha V. Demography and disease characteristics of prostate cancer in India. Indian J Urol 2016; 32 (02) 103-108
    CrossrefPubMedSearch in Google Scholar
  • 3 Hebert JR, Ghumare SS, Gupta PC. Stage at diagnosis and relative differences in breast and prostate cancer incidence in India: comparison with the United States. Asian Pac J Cancer Prev 2006; 7 (04) 547-555
    PubMedSearch in Google Scholar
  • 4 Cronin KA, Ries LA, Edwards BK. The surveillance, epidemiology, and end results (SEER) program of the National Cancer Institute. Cancer 2014; 120 (Suppl. 23) 3755-3757
    CrossrefPubMedSearch in Google Scholar
  • 5 Howlader N, Noone AM, Krapcho M, et al. eds. SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations). Bethesda, MD: National Cancer Institute; 2012. Available at: https://seer.cancer.gov/archive/csr/1975_2008/. Accessed May 19, 2019
  • 6 Lilja H, Cronin AM, Dahlin A. et al. Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer 2011; 117 (06) 1210-1219
    CrossrefPubMedSearch in Google Scholar
  • 7 Walsh PC. Why make an early diagnosis of prostate cancer. J Urol 1992; 147 (3 Pt 2) 853-854
    CrossrefPubMedSearch in Google Scholar
  • 8 Andriole GL, Crawford ED, Grubb III RL. et al. PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360 (13) 1310-1319
    CrossrefPubMedSearch in Google Scholar
  • 9 Dianat SS, Rancier Ruiz RM, Bonekamp D, Carter HB, Macura KJ. Prostate volumetric assessment by magnetic resonance imaging and transrectal ultrasound: impact of variation in calculated prostate-specific antigen density on patient eligibility for active surveillance program. J Comput Assist Tomogr 2013; 37 (04) 589-595
    CrossrefPubMedSearch in Google Scholar
  • 10 Lazzeri M, Abrate A, Lughezzani G. et al. Relationship of chronic histologic prostatic inflammation in biopsy specimens with serum isoform [-2]proPSA (p2PSA), %p2PSA, and prostate health index in men with a total prostate-specific antigen of 4-10 ng/ml and normal digital rectal examination. Urology 2014; 83 (03) 606-612
    CrossrefPubMedSearch in Google Scholar
  • 11 Serdar MA, Oguz O, Olgun A. et al. Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together. Ann Clin Lab Sci 2002; 32 (01) 22-30
    PubMedSearch in Google Scholar
  • 12 Xie SW, Wang YQ, Dong BJ. et al. A nomogram based on a TRUS Five-grade scoring system for the prediction of prostate cancer and high grade prostate cancer at initial TRUS-Guided Biopsy. J Cancer 2018; 9 (23) 4382-4390
    CrossrefPubMedSearch in Google Scholar
  • 13 Tijani KH, Anunobi CC, Adeyomoye AO. et al. The role of the percentage free PSA in the diagnosis of prostate cancer in Blacks: findings in indigenous West African men using TRUS guided biopsy. Afr J Urol 2017; 23 (01) 14-19
    CrossrefSearch in Google Scholar
  • 14 Catalona WJ, Smith DS, Wolfert RL. et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995; 274 (15) 1214-1220
    CrossrefPubMedSearch in Google Scholar
  • 15 Fowler Jr JE, Sanders J, Bigler SA, Rigdon J, Kilambi NK, Land SA. Percent free prostate specific antigen and cancer detection in black and white men with total prostate specific antigen 2.5 to 9.9 ng/ml. J Urol 2000; 163 (05) 1467-1470
    CrossrefPubMedSearch in Google Scholar
  • 16 Ezenwa EV, Tijani KH, Jeje EA. et al. The value of percentage free prostate specific antigen (PSA) in the detection of prostate cancer among patients with intermediate levels of total PSA (4.0-10.0 ng/mL) in Nigeria. Arab J Urol 2012; 10 (04) 394-400
    CrossrefPubMedSearch in Google Scholar
  • 17 Lowe FC, Trauzzi SJ. Prostatic acid phosphatase in 1993. Its limited clinical utility. Urol Clin North Am 1993; 20 (04) 589-595
    CrossrefPubMedSearch in Google Scholar
  • 18 Catalona WJ, Richie JP, Ahmann FR. et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151 (05) 1283-1290
    CrossrefPubMedSearch in Google Scholar
  • 19 Nam RK, Toi A, Klotz LH. et al. Assessing individual risk for prostate cancer. J Clin Oncol 2007; 25 (24) 3582-3588
    CrossrefPubMedSearch in Google Scholar
  • 20 Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM. Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med 2012; 4 (127) 127rv3
    CrossrefPubMedSearch in Google Scholar
  • 21 Potosky AL, Feuer EJ, Levin DL. Impact of screening on incidence and mortality of prostate cancer in the United States. Epidemiol Rev 2001; 23 (01) 181-186
    CrossrefPubMedSearch in Google Scholar
  • 22 Jeong IG, Lim JH, Hwang SS. et al. Nomogram using transrectal ultrasound-derived information predicting the detection of high grade prostate cancer on initial biopsy. Prostate Int 2013; 1 (02) 69-75
    CrossrefPubMedSearch in Google Scholar
  • 23 Sfoungaristos S, Perimenis P. Evaluating PSA density as a predictor of biochemical failure after radical prostatectomy: results of a prospective study after a median follow-up of 36 months. ISRN Urol 2013; 2013: 984951
    PubMedSearch in Google Scholar
  • 24 Ferro M, Buonerba C, Terracciano D. et al. Biomarkers in localized prostate cancer. Future Oncol 2016; 12 (03) 399-411
    CrossrefPubMedSearch in Google Scholar